amifostine anhydrous has been researched along with bortezomib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Avan, A; Cavaletti, G; Ceresa, C; Geldof, AA; Giovannetti, E; Peters, GJ | 1 |
1 review(s) available for amifostine anhydrous and bortezomib
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for amifostine anhydrous and bortezomib
| Article | Year |
|---|---|
Characterization of and protection from neurotoxicity induced by oxaliplatin, bortezomib and epothilone-B.
Topics: Adrenal Gland Neoplasms; Amifostine; Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Differentiation; Cyclin B2; Epothilones; Microtubule-Associated Proteins; Neurites; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Pheochromocytoma; Pyrazines; Radiation-Protective Agents; Rats; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survivin; Tumor Cells, Cultured | 2014 |